Semaglutide vs. Tirzepatide for Weight Loss: A Head-to-Head Comparison for 2026

Key takeaways

• Tirzepatide produced more average weight loss than semaglutide in trials: about 18–21% versus about 15% of body weight.
• Semaglutide acts on one gut-hormone receptor. Tirzepatide acts on two, and that is the core difference.
• Both share the same gut side effects, mainly nausea, vomiting and diarrhea.
• In Michigan, cost and coverage often decide the choice as much as the trial data does.
• Tirzepatide is often preferred when there is more weight to lose, but your history decides the answer.

How Do They Work? Single vs. Dual Agonist

The core difference is how each drug works in the body.

• Semaglutide is a GLP-1 receptor agonist (a drug that copies GLP-1, an incretin, or gut hormone released after meals). It slows how fast the stomach empties. It boosts fullness signals to the brain. It also improves insulin sensitivity (how well your cells respond to insulin, the hormone that moves sugar from blood into cells).
• Tirzepatide is a dual GLP-1/GIP receptor agonist. It switches on both the GLP-1 receptor and the GIP receptor (GIP is glucose-dependent insulinotropic polypeptide, a second gut hormone). That gives it a two-pronged effect on appetite, blood sugar and fat burning.

This dual action is what gives tirzepatide a possible edge in clinical trials. It reaches metabolic pathways that semaglutide alone does not.

Four brand names, two molecules. Semaglutide is sold as Ozempic (diabetes label) and Wegovy (weight label). Tirzepatide is sold as Mounjaro (diabetes label) and Zepbound (weight label). This page compares the two molecules themselves. For the brand-by-brand versions, read Mounjaro vs Ozempic and Wegovy vs Zepbound.

What Does the Clinical Data Show on Weight Loss?

In real-world data, semaglutide users classed as "achievers" lost 4.7–10.5 kg at 6–12 months. That finding comes from a 2026 narrative review that compared real-world results with trial data (Journal of Diabetes, Bloomgarden, 2026). The same review cites the SHAPE study. There, "persisters" (people who stayed on the drug) lost about 14.1% of body weight on semaglutide and about 16.5% on tirzepatide.

Trial estimates were higher. Randomized controlled trials (RCTs: studies where people are assigned by chance to a treatment or a placebo) put semaglutide at about 14.9%. They put tirzepatide 15 mg at about 20.9%. Those are per-protocol figures, which count only people who took the drug as planned.

A 2024 network meta-analysis (a study that pools the results of many trials) pointed the same way. It combined 25 RCTs with 18,257 patients. Tirzepatide significantly outperformed the other treatments, including semaglutide. That held for both weight loss and HbA1c (your average blood sugar over the past three months) (Biomedicines, Ayesh et al., 2024).

How Do They Compare Head-to-Head?

• Mechanism: Semaglutide = GLP-1 agonist | Tirzepatide = GLP-1 + GIP dual agonist.
• Average weight loss (RCT): Semaglutide ~15% | Tirzepatide ~18–21% of body weight.
• Max dose: Semaglutide 2.4 mg weekly | Tirzepatide 15 mg weekly.
• How it is given: Both are a weekly subcutaneous injection (a small shot under the skin).
• Common side effects: Both - nausea, diarrhea, constipation.
• Dose escalation (stepping up to the full dose): Semaglutide 16–20 weeks | Tirzepatide 20–28 weeks to max dose.
• Monthly cost (without insurance): Semaglutide $350–$600 (compounded, historical) to $1,300+ (brand) | Tirzepatide $400–$700 (compounded, historical) to $1,100+ (brand).

The compounded figures above are historical. Compounded drugs (custom-mixed by a pharmacy rather than made in a factory) are no longer routinely available for semaglutide or tirzepatide in the United States. That changed in 2025, when the FDA shortage listing ended and the FDA's leeway for compounding ended with it. Our guide to compounded vs brand semaglutide has the full picture.

Side Effects: How Do They Compare?

Both drugs share the same gastrointestinal (stomach and gut) side effects:

• Nausea.
• Vomiting.
• Diarrhea.
• Constipation.

These are most common while the dose is being stepped up. They usually fade over time. Key differences:

• Nausea rates are similar for the two drugs when the dose is raised at the same speed.
• Discontinuation (stopping the drug) is common with both in real-world data. The 2026 Journal of Diabetes review found that 20–50% of patients stopped within one year. The most common reasons were side effects, cost, or access problems.
• Cardiovascular safety (heart and blood vessels): Semaglutide has shown 20–46% reductions in MACE (major adverse cardiovascular events, such as heart attack and stroke) in real-world studies. Head-to-head heart-outcome trials of the two drugs in people without diabetes are still needed.

Not sure which one fits you?
Your $35 first visit at Arbour Longevity in Ann Arbor is a 30–45 minute visit to work out which GLP-1 fits you, with the $35 applied toward your plan.
Book your $35 first visit Call (734) 436-3357

What Do They Cost in Michigan?

Cost is often the deciding factor for patients. In Michigan, the picture changed a lot in 2026:

• Medicare: CMS launched a new $50/month GLP-1 access program for people on Medicare. It cuts costs sharply for patients who qualify.
• Michigan Medicaid: Medicaid went the other way. It limited GLP-1 coverage for weight loss, cutting about $240 million in spending.
• Private insurance: Coverage varies widely. Many plans cover GLP-1 drugs for type 2 diabetes but not for weight management alone.
• Compounded options: No longer a routine pathway. Semaglutide came off the FDA shortage list on 21 February 2025. FDA enforcement discretion for compounding then ended on 22 April 2025 for 503A pharmacies and on 22 May 2025 for 503B outsourcing facilities. On 30 April 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List. The proposal was published in the Federal Register on 1 May 2026, and the comment period was extended to 30 July 2026. No final decision could be confirmed as of August 2026. See compounded vs brand semaglutide for the full picture.

At Arbour Longevity, we prescribe FDA-approved brand GLP-1 drugs. We then work with you to find the lowest-cost way to get them. That includes help with insurance approval and transparent monthly pricing.

Which One Is Right for You?

Tirzepatide may be the better choice if:

• You have a lot of weight to lose (BMI 35+).
• You also have type 2 diabetes or marked insulin resistance (your cells stop responding to insulin, so blood sugar and belly fat rise).
• You want the most weight-loss potential supported by current data.

Semaglutide may be the better choice if:

• You have heart-disease risk factors (stronger MACE reduction data).
• You prefer a drug with a longer real-world safety track record.
• Cost is a top concern and your insurance favors semaglutide.
• You have a moderate amount of weight to lose.

In the end, the best drug is the one you can tolerate, afford, and stay on at the target dose.

Our Approach at Arbour Longevity

Medical weight loss at Arbour Longevity goes beyond a GLP-1 prescription. Gandhi Bhattarai, FNP-BC, PMHNP-BC takes a whole-person approach that may include:

• Full metabolic lab work before you start any drug.
• Hormone care (BHRT, hormones that match the ones your body makes) to address hidden metabolic imbalances.
• Peptide therapy to support mitochondrial function and gut health. Peptides are short chains of amino acids that act as cell signals; mitochondria are the tiny power plants inside your cells.
• Body composition tracking (muscle versus fat) to make sure you lose fat, not muscle.
• Ongoing dose titration (adjusting the dose step by step) and help with side effects.

This whole-person model is what separates a longevity clinic from a GLP-1 prescription mill.

Frequently Asked Questions

Can I switch from semaglutide to tirzepatide (or vice versa)?

Yes. Switching is common when someone plateaus on one drug or cannot tolerate its side effects. Your provider will set the right starting dose for the new drug based on your current dose and response. Our companion guide, switching from semaglutide to tirzepatide, walks through the whole move: the timing, the dose ladder, and what the first two months feel like.

Will I regain weight if I stop taking GLP-1 medications?

Studies show that weight regain is common after stopping. That is why lifestyle changes and better metabolic health are core parts of any medical weight loss program. At Arbour Longevity, we build long-term strategies, not just prescriptions.

Can I still get compounded semaglutide or tirzepatide?

Not as a routine option. Semaglutide came off the FDA shortage list on 21 February 2025. The enforcement discretion that had allowed wide compounding ended on 22 April 2025 for 503A pharmacies and on 22 May 2025 for 503B outsourcing facilities. FDA has since proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List. Arbour Longevity does not routinely supply compounded GLP-1 drugs. Our guide to compounded vs brand semaglutide explains where things stand.

How soon will I see results?

Most patients notice less appetite within the first 1–2 weeks. Weight loss you can measure usually starts within the first month. The biggest results tend to come at 3–6 months, as you reach your optimal dose.

Find out which GLP-1 drug is right for you. You can book your $35 first visit at Arbour Longevity in Ann Arbor, or call (734) 436-3357. We will review your labs, medical history, and weight loss goals. Then we will recommend the best drug and build a full plan for lasting results.

This article is educational and does not replace individualized medical advice.